Gainers

• Cypherpunk Technologies (NASDAQ:CYPH) shares moved upwards by 14.9% to $1.0 during Tuesday's after-market session. The company's market cap stands at $46.7 million.
• CytoMed Therapeutics (NASDAQ:GDTC) shares rose 9.98% to $0.88. The market value of their outstanding shares is at $10.4 million.
• Xenetic Biosciences (NASDAQ:XBIO) shares increased by 6.58% to $2.75. The company's market cap stands at $5.8 million.
• VolitionRX (AMEX:VNRX) shares moved upwards by 6.54% to $0.28. The company's market cap stands at $32.7 million.
• Novartis (NYSE:NVS) stock increased by 4.32% to $158.8. The market value of their outstanding shares is at $286.1 billion.
• Astrana Health (NASDAQ:ASTH) shares moved upwards by 3.89% to $22.32. The company's market cap stands at $1.3 billion.

Losers

• Century Therapeutics (NASDAQ:IPSC) shares decreased by 7.7% to $2.45 during Tuesday's after-market session. The market value of their outstanding shares is at $225.2 million.
• Exicure (NASDAQ:XCUR) shares decreased by 4.47% to $4.25. The market value of their outstanding shares is at $32.1 million.
• USBC (AMEX:USBC) shares fell 4.34% to $0.64. The market value of their outstanding shares is at $219.3 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock declined by 3.64% to $0.1. The company's market cap stands at $10.5 million.
• Genenta Science (NASDAQ:GNTA) stock declined by 3.25% to $1.49. The market value of their outstanding shares is at $30.4 million.
• INVO Fertility (NASDAQ:IVF) stock fell 2.63% to $1.67. The market value of their outstanding shares is at $18.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.